medhya rasayana – Ayurved Healing

Medhya Herbs for Perimenopause Brain Fog: Targeting Cognitive Decline in Transition

Priya Nair — Tue, 14 Jul 2026 09:00:00 +0000

“I am walking into rooms and forgetting why. I am in the middle of sentences and losing the word I need. I feel like I am thinking through cotton wool.” These words, or some version of them, are familiar in perimenopause care. Brain fog during this transition commonly shows up as word-finding difficulty, forgetfulness, poor concentration, slower task switching, and losing the thread of a thought.

Perimenopause brain fog deserves to be taken seriously. It is not a failure of willpower, and it is not always “just stress.” The menopause transition is a body-brain transition in which changing ovarian hormones, sleep disruption, vasomotor symptoms, mood strain, and metabolic shifts can all affect attention, memory, and verbal recall.

Ayurvedic Medhya Rasayana — the class of rejuvenative herbs and practices used to support medha, buddhi, dhi, dhriti, and smriti — offers a thoughtful framework for cognitive support during this transition. The aim is not to force stimulation, but to steady Vata, cool aggravated Pitta, nourish depleted tissues, protect sleep, and support the channels through which the mind and senses function.

The Ayurvedic Explanation: Vata Transition, Manovaha Srotas and Ojas

Ayurveda describes a broad life-stage movement from Kapha predominance in childhood, through Pitta predominance in adulthood, toward Vata predominance in later life. Perimenopause sits near this Pitta-to-Vata crossing for many women: cycles become less predictable, heat may rise, sleep may fragment, dryness may increase, and the mind can feel less anchored.

In Ayurvedic language, perimenopause brain fog can be understood as Vata-Pitta disturbance affecting Manovaha Srotas, the channels through which mind and body interact. Vata contributes mobility, irregularity, quick shifting of attention, interrupted sleep, and a scattered feeling. Pitta contributes heat, irritability, intensity, and pressure. When Rasa, Majja, and Ojas are not well nourished, Smriti — memory and recall — becomes less reliable.

Ojas is the refined vitality associated with well-nourished dhatus, strength, resilience, and steadiness. In a perimenopausal woman who is sleeping poorly, under-eating, over-working, bleeding heavily, or living under sustained stress, the ojas-like quality of stability can weaken. A Medhya Rasayana approach therefore asks two questions at once: how do we support memory and clarity, and how do we rebuild the ground that memory depends on?

The Four Medhya Rasayana Herbs in Charaka Samhita

Charaka Samhita, Chikitsa Sthana 1/3/30-31, lists four principal Medhya Rasayana substances: Mandukaparni swarasa, Yashtimadhu churna with milk, Guduchi swarasa, and Shankhapushpi kalka. They are described as life-promoting, strength-promoting, agni-supporting, complexion-supporting, voice-supporting, and intellect-promoting, with Shankhapushpi singled out for its medhya action.

1. Mandukaparni (Centella asiatica, Gotu Kola)

Mandukaparni is the fresh-juice Medhya herb in Charaka’s list. It is best suited to the perimenopause patient whose brain fog feels like poor retention, distracted attention, mental fatigue, and difficulty staying present. In the Ayurvedic Pharmacopoeia of India, Mandukaparni is identified as the dried whole plant of Centella asiatica. Classical use favours fresh swarasa when available, while modern clinical use often relies on powder, liquid extract, or standardised extract chosen by the practitioner.

In a perimenopause protocol, Mandukaparni is usually the daytime clarity herb. It should not be confused with Bacopa-based Brahmi preparations unless the practitioner has intentionally chosen Bacopa as a separate Medhya herb. Mandukaparni is gentler when digestion is stable, sleep is protected, and the patient is not relying on stimulants to push through exhaustion.

2. Yashtimadhu (Glycyrrhiza glabra, Licorice Root)

Yashtimadhu appears in Charaka’s Medhya Rasayana list as churna taken with milk. Its Ayurvedic profile is sweet, nourishing, demulcent, and Vata-Pitta soothing, making it relevant when perimenopause brain fog comes with dryness, depleted voice, burning, irritability, or a sense of being overdrawn. It is not a herb for casual long-term self-prescribing.

Licorice contains glycyrrhizin, which can raise blood pressure, lower potassium, and create serious cardiovascular risk in susceptible people. Yashtimadhu should be avoided or used only with medical supervision in hypertension, kidney disease, heart disease, oedema, low potassium, pregnancy, and with medicines that affect blood pressure, potassium, heart rhythm, or fluid balance.

3. Guduchi (Tinospora cordifolia)

Guduchi is listed by Charaka as swarasa, and the Ayurvedic Pharmacopoeia of India identifies the drug as dried mature stem of Tinospora cordifolia. In a perimenopause brain-fog pattern, Guduchi is most appropriate when mental dullness is accompanied by heat, low resilience, post-illness depletion, poor agni, inflammatory tendencies, or the sense that the system has become reactive rather than steady.

Modern pharmacology has described cholinesterase-inhibiting constituents from Tinospora cordifolia, which fits its traditional positioning as a medhya-rasayana support rather than a simple stimulant. Guduchi should still be selected carefully. People with liver disease, abnormal liver enzymes, autoimmune disease, or those taking immunosuppressive medicines should use it only under qualified supervision.

4. Shankhapushpi (Convolvulus pluricaulis)

Shankhapushpi appears in Charaka’s Medhya Rasayana list as kalka and is singled out as especially intellect-promoting. In perimenopause, it is often most useful when brain fog is inseparable from a racing mind, anxious sleep, irritability, and difficulty settling at night. This is the evening member of the Medhya plan: it supports clarity by first supporting calm.

Traditional use often combines Shankhapushpi with warm milk, ghee, or a suitable anupana, because perimenopausal Vata responds better to nourishment than to dry stimulation. If the person is sedated, taking sleep medicines, or using anxiety medication, Shankhapushpi should be supervised by a practitioner.

The Shatavari Connection: Supporting the Hormonal-Cognitive Terrain

Shatavari (Asparagus racemosus) is not one of Charaka’s four Medhya Rasayana herbs, but it is highly relevant to the perimenopause terrain. Its classical use as a nourishing female rasayana, lactation-supporting herb, and reproductive-system support makes it a useful companion when brain fog is tied to hot flushes, night waking, dryness, mood strain, and the feeling of hormonal depletion.

Modern menopause and perimenopause trials of Shatavari root extract have focused on symptom burden, quality of life, sleep, mood, vasomotor symptoms, and tolerability. That makes Shatavari best framed as support for the hormonal-sleep-mood axis around cognition, not as a direct replacement for the four Medhya Rasayana herbs.

A Practical Medhya Stack for Perimenopause Brain Fog

A safe perimenopause Medhya plan is built gradually. Start with digestion, sleep, and one or two well-matched herbs before combining many products. The table below is an educational framework; the exact dose, form, duration, and anupana should be individualised by a qualified Ayurvedic practitioner.

Herb	Best Fit in Perimenopause Brain Fog	Classical / Practical Form	Usual Timing
Mandukaparni	Distracted attention, poor retention, daytime mental fatigue	Fresh swarasa when available; otherwise practitioner-selected powder or extract	Morning or early day
Guduchi	Brain fog with heat, low resilience, poor agni, post-illness depletion	Swarasa, stem powder, decoction, or extract as prescribed	Morning or afternoon
Shankhapushpi	Fog linked with anxiety, racing thoughts, and poor sleep	Kalka, powder, ghrita, syrup, or extract as prescribed	Evening
Yashtimadhu	Dry, depleted, Vata-Pitta brain fog when blood pressure and potassium risk are absent	Short-course churna with milk or supervised extract	Morning; limited duration
Shatavari	Hot flushes, night waking, dryness, mood strain, hormonal depletion pattern	Root powder, kalpa, milk preparation, or standardised extract as prescribed	Evening or divided dose

If your practitioner uses Brahmi to mean Bacopa monnieri, treat it as a separate Medhya herb rather than as a silent substitute for Mandukaparni in Charaka’s four-herb list. Bacopa may be useful in some cognitive protocols, but it is best added deliberately, especially if the person is already using sedatives, thyroid medication, antidepressants, or multiple calming herbs.

Lifestyle Foundations That Amplify Medhya Herb Effects

Medhya herbs work best when Manovaha Srotas is not being disturbed every night by poor sleep, excess stimulation, erratic meals, and unmanaged heat. The foundational practices below are simple, but they often decide whether the herbs feel clear and nourishing or heavy and ineffective.

Quiet early-morning recall practice: Brahma Muhurta is traditionally praised as a favourable time for waking, reflection, prayer, study, and subtle mental work. In perimenopause, this should never mean sacrificing sleep. If waking before sunrise worsens fatigue, choose a later quiet window for journaling, mantra, memorisation, or planning.
Gentle Pratimarsha Nasya: Classical Ayurveda describes the nose as the gateway to the head. When appropriate, a practitioner may advise a very small daily dose of suitable nasal oil to support the head, senses, and Vata steadiness. Avoid nasya during acute sinus infection, heavy congestion, fever, immediately after meals, or without guidance if pregnant or medically complex.
Abhyanga, especially scalp, neck, and feet: Warm oil massage is a direct Vata-pacifying practice. For brain fog with poor sleep, evening foot massage and gentle scalp or neck oiling can be more useful than adding another stimulating supplement.
Stable meals and protected sleep: Skipping breakfast, eating late, drinking alcohol at night, and leaning on caffeine can aggravate Vata-Pitta patterns. Warm, protein-containing meals, a regular bedtime, a cooler sleeping environment, and a calmer evening routine support the same cognitive terrain that Medhya herbs are meant to nourish.

For companion reading: the complete Ayurvedic perimenopause protocol, our guide to cognitive decline prevention over 70, and Bacopa monnieri clinical dosage guide.

Safety: Sudden, progressive, or severe cognitive change needs medical assessment, especially if accompanied by confusion, fainting, weakness, severe headache, heavy bleeding, anaemia, thyroid disease, major mood change, medication changes, or suspected pregnancy. Use herbs only with a qualified Ayurvedic practitioner or healthcare provider, especially if using HRT, antidepressants, sedatives, blood-pressure medicines, anticoagulants, diabetes medicines, immunosuppressants, or if there is liver disease, kidney disease, autoimmune disease, hypertension, low potassium, pregnancy, breastfeeding, or a history of oestrogen-sensitive cancer.

Nothing in this article diagnoses or treats a medical condition. It is educational information and should be personalised by a qualified practitioner.

References

Medhya Rasayana Deep Dive: 4 Classical Nootropic Herbs and Their Neuroscience

Dr. Meera Iyer — Sat, 27 Jun 2026 12:00:00 +0000

The Charaka Samhita, Chikitsa Sthana 1, Karaprachitiya Rasayana Pada, verses 30-31, presents four Medhya Rasayana herbs with specific forms of administration: Mandukaparni svarasa, Yashtimadhu powder with milk, Guduchi juice, and Shankhapushpi kalka. The passage describes them as rasayana drugs that promote life, reduce disease, support strength, agni, complexion, voice, and medha, with Shankhapushpi singled out as especially medhya.

This is a precise classical formulation rather than a generic “brain tonic” list. Each herb has a different dravya profile, vehicle, and preparation, and modern pharmacology gives plausible but uneven mechanistic parallels for their traditional use. The best way to read this group is as a classical cognitive-rasayana framework that spans nourishment, calm attention, inflammatory resilience, and mental clarity, not as four interchangeable nootropics.

What Medhya Rasayana Means in the Classical Framework

Medhya refers to that which supports medha, the faculty connected with grasping, retaining, recalling, and applying knowledge. In Ayurvedic discussions of mental function, medha is commonly linked with dhi, dhriti, and smriti: understanding or discernment, steadiness or retention, and memory. Rasayana refers to therapies and disciplines that support the quality of dhatus, strength, longevity, and functional resilience. Medhya Rasayana therefore occupies a specific place within rasayana: it is rejuvenative care directed toward the mind, memory, intellect, and nervous-system vitality.

The Charaka passage does not describe one universal extract or one uniform mechanism. It names four herbs and four forms: fresh juice for Mandukaparni, Yashtimadhu powder taken with milk, Guduchi juice, and paste of Shankhapushpi. This classical specificity is important because Ayurveda treats the herb, preparation, vehicle, dose, prakriti, agni, and clinical context as part of one therapeutic decision.

Mandukaparni (Centella asiatica): svarasa, or fresh juice.
Yashtimadhu (Glycyrrhiza glabra): powder taken with milk.
Guduchi (Tinospora cordifolia): juice of the plant.
Shankhapushpi (Convolvulus pluricaulis): kalka, or paste.

Mandukaparni: Calm Attention, Memory Support, and Neuroplasticity

Mandukaparni is identified in the Ayurvedic Pharmacopoeia of India as the dried whole plant of Centella asiatica. Its API profile lists madhura, katu, tikta, and kashaya rasa; laghu and sara guna; sheeta virya; madhura vipaka; and actions including medhya, smritiprada, rasayana, dipana, hridya, balya, and ayushya. This makes Mandukaparni a classical choice where memory support is needed without adding excessive heat or stimulation.

Modern work on Centella asiatica focuses mainly on triterpenoid saponins such as asiaticoside, madecassoside, asiatic acid, and madecassic acid, along with antioxidant and mitochondrial pathways. Human work is limited but includes a randomized, placebo-controlled trial in healthy elderly volunteers using Centella asiatica extract for two months, where cognitive and mood-related measures were assessed. Experimental models also describe effects on BDNF expression, oxidative stress, and synaptic or mitochondrial function, which fit the classical picture of Mandukaparni as a steadying, restorative medhya herb.

Classically, Mandukaparni is not used merely as a sedative. Its value lies in the combination of mental steadiness, memory support, and cooling pitta-pacifying action. In practical Ayurvedic use, it is often considered when excess mental heat, restlessness, poor retention, or stress-related distraction accompanies weak concentration.

Yashtimadhu: Nourishing Medhya Support with Clear Safety Boundaries

Yashtimadhu is identified in the Ayurvedic Pharmacopoeia of India as the dried unpeeled stolon and root of Glycyrrhiza glabra. Its API profile lists madhura rasa, guru and snigdha guna, sheeta virya, madhura vipaka, and actions such as balya, vrishya, varnya, raktaprasadana, and vatapittajit. In Charaka’s Medhya Rasayana passage it is specifically taken as powder with milk, emphasizing its nourishing and cooling vehicle rather than a harsh stimulant effect.

Modern pharmacological descriptions of licorice center on glycyrrhizin, glycyrrhizic acid, glycyrrhetinic acid, and flavonoids. These compounds are mainly discussed for anti-inflammatory, antioxidant, endocrine, and mucosal-protective actions. For a Medhya Rasayana reading, Yashtimadhu is best understood as a supportive, nourishing herb that may be suited to vata-pitta depletion patterns rather than as a stand-alone memory drug.

The safety boundary is essential. Glycyrrhizin-containing licorice can cause pseudoaldosteronism, hypertension, edema, and low potassium, especially with high dose, long duration, kidney disease, hypertension, diuretic use, corticosteroid use, or other cardiovascular risk. Deglycyrrhizinated licorice may reduce blood-pressure risk for gastrointestinal uses, but it is not identical to the classical Yashtimadhu Medhya Rasayana described with milk.

Guduchi: Rasayana Resilience and Inflammatory Stress

Guduchi is identified in the Ayurvedic Pharmacopoeia of India as the dried mature stem of Tinospora cordifolia, with the fresh form also recognized. Its API profile lists tikta and kashaya rasa, laghu guna, ushna virya, madhura vipaka, and actions including balya, dipana, rasayana, sangrahi, tridoshashamaka, raktashodhaka, and jvaraghna. In the Medhya Rasayana group, Guduchi contributes a broad rasayana quality rather than a narrow stimulant action.

Modern experimental literature places Guduchi within immunomodulatory, anti-inflammatory, antioxidant, and neuroprotective discussions. In animal models, Tinospora cordifolia extract has been studied for glial activation, cytokine expression, oxidative stress, and behavior under neuroinflammatory or stress conditions. This modern lens pairs well with the classical use of Guduchi where cognitive dullness, fatigue, post-illness weakness, or inflammatory stress coexists with impaired clarity.

Guduchi should not be used casually as an unlimited “immunity booster.” Its immune activity makes supervision important in autoimmune disease, transplant medicine, immunosuppressant use, chronic liver disease, or unexplained abnormal liver enzymes. Published liver-injury reports and official safety statements both exist, so clinical context and botanical authenticity matter.

Shankhapushpi: The Herb Singled Out as Especially Medhya

Shankhapushpi is identified in the Ayurvedic Pharmacopoeia of India as the whole plant of Convolvulus pluricaulis. Its API profile lists katu, tikta, and kashaya rasa; sara guna; sheeta virya; katu vipaka; and actions including medhya, rasayana, ayushya, balya, kaphahara, pittahara, and mohanashaka. The API also notes that in certain parts of India, Clitoria ternatea and Evolvulus alsinoides are used as Shankhapushpi, making botanical identity especially important.

Charaka gives Shankhapushpi special emphasis among the four Medhya Rasayana herbs. Its kalka form suggests a whole-plant preparation rather than a single isolated constituent approach. Experimental work on Convolvulus pluricaulis includes hippocampal synaptic plasticity models and neuropharmacological animal work, which suits its classical placement as a medhya rasayana directed toward clarity, learning, and mental steadiness.

The most important safety point is its interaction with phenytoin. A published interaction study on Shankhapushpi and phenytoin described reduced antiepileptic activity in rats, and repeated coadministration also reduced plasma phenytoin levels. Anyone with epilepsy, seizure history, or antiepileptic medication use should avoid Shankhapushpi unless a neurologist and qualified Ayurvedic physician are both involved.

Comparison of the Four Classical Medhya Rasayana Herbs

The four herbs can be compared across their classical form, Ayurvedic profile, modern pharmacological lens, and practical cautions. This table uses classical Charaka preparation forms and API dose ranges where available; it should not be read as a self-prescription chart.

Herb	Classical Form in Charaka	API Ayurvedic Profile	Modern Pharmacology Lens	API Dose Range	Key Caution
Mandukaparni (Centella asiatica)	Svarasa, fresh juice	Medhya, smritiprada, rasayana; sheeta virya; madhura vipaka	Triterpenoid saponins, antioxidant and mitochondrial pathways, BDNF-related animal work, limited human cognitive data	3-6 g dried whole plant	Use cautiously with sedatives, liver disease, pregnancy, or prolonged unsupervised use
Yashtimadhu (Glycyrrhiza glabra)	Powder with milk	Madhura, guru, snigdha, sheeta; vatapittajit and balya	Glycyrrhizin, glycyrrhetinic acid, flavonoids; anti-inflammatory and endocrine-related activity	2-4 g root/stolon powder	Can raise blood pressure and lower potassium; avoid unsupervised use in hypertension, kidney disease, edema, or diuretic use
Guduchi (Tinospora cordifolia)	Juice of Guduchi	Rasayana, tridoshashamaka, balya, dipana; ushna virya; madhura vipaka	Immunomodulatory, anti-inflammatory, antioxidant, and neuroinflammation-related animal work	3-6 g powder or 20-30 g for decoction	Use cautiously in autoimmune disease, liver disease, transplant medicine, or immunosuppressant therapy
Shankhapushpi (Convolvulus pluricaulis)	Kalka, paste	Medhya, rasayana, ayushya, balya; sheeta virya; katu vipaka	Synaptic plasticity and neuropharmacological animal work; limited human data	3-8 g whole-plant powder	Avoid with phenytoin or seizure medication unless supervised by a physician

Why the Combination Is More Than a Single-Pathway Nootropic

The classical combination is multidimensional. Mandukaparni leans toward cooling medhya and smriti support; Yashtimadhu adds nourishment, cooling, and vata-pitta balancing through a milk vehicle; Guduchi adds rasayana resilience, agni support, and tridosha-balancing; Shankhapushpi is the herb directly singled out as especially medhya. Together, they represent an Ayurvedic model in which cognition depends not only on neurotransmitters, but also on agni, ojas, dhatu nourishment, sleep, emotional steadiness, and the balance of doshas.

Modern pharmacology should be used as a translation layer, not as a replacement for Ayurvedic reasoning. The available data are strongest for preclinical mechanisms and limited human work, especially for Mandukaparni. For Yashtimadhu, Guduchi, and Shankhapushpi, modern data are useful for safety and mechanistic context, but clinical decisions still require individual assessment.

Minimum Effective Use and Practical Application

Medhya Rasayana is not meant to act like a one-time stimulant. It is traditionally used as a planned course with attention to dose, season, digestion, sleep, food, and the patient’s constitution. In clinical practice, a qualified Ayurvedic physician may choose a single herb, a classical formulation, or a modified combination depending on whether the person presents with anxiety, heat, depletion, post-illness fatigue, kapha dullness, insomnia, medication use, or age-related memory concern.

For a broader discussion of clinical dosing logic in another medhya herb, see our related article on Bacopa monnieri dosage: what clinical trials actually used. For adaptogens related to brain health, see our review of how adaptogens actually work: the cellular mechanisms behind Ashwagandha and Brahmi.

Disclaimer: This article is educational and does not diagnose, treat, or prevent any neurological, psychiatric, or cognitive disorder. Medhya Rasayana herbs are not substitutes for medical evaluation in memory loss, seizures, depression, anxiety, dementia, head injury, sleep disorders, or medication-related cognitive symptoms. Consult a qualified Ayurvedic physician and an appropriate healthcare provider before using these herbs, especially if pregnant, breastfeeding, elderly, managing liver, kidney, autoimmune, cardiovascular, neurological, or psychiatric conditions, or taking prescription medication.

References

Nootropics vs Medhya Rasayanas: A Head-to-Head Evidence Comparison

Dr. Meera Iyer — Mon, 15 Jun 2026 07:30:00 +0000

When a researcher at a major neuroscience institute asked me whether Ayurvedic brain herbs could “actually compete with modafinil,” my answer was: competing on what metric? The question itself reveals a category error. Modafinil and Brahmi are not attempting the same thing — they operate through different mechanisms, on different timescales, with different risk profiles and different definitions of “better cognition.” Understanding these differences with precision is more useful than declaring a winner.

This comparison will cover the four classical Medhya Rasayanas — herbs classified in Charaka Samhita Chikitsa Sthana Chapter 1 as specifically promoting Medha (intelligence, memory, learning capacity) — alongside the major categories of modern pharmaceutical and nutraceutical nootropics. I will use the same evidence-evaluation framework for both: mechanism of action, human RCT evidence, effect size, safety profile, and appropriate use case.

The Medhya Rasayanas: Classical Classification

In Charaka Samhita, Chikitsa Sthana Chapter 1 (Rasayana Adhyaya, Karaprachitiya Rasayana Pada), four herbs are named explicitly as Medhya Rasayana — substances that specifically promote Medha. Each is given with a particular preparation and vehicle (anupana):

Mandukaparni (Centella asiatica): as swarasa (fresh expressed juice)
Yastimadhu (Glycyrrhiza glabra, licorice): as churna (powder) taken with milk (kshira)
Guduchi (Tinospora cordifolia): as swarasa (fresh juice)
Shankhapushpi (Convolvulus pluricaulis): as kalka (fresh whole-plant paste)

A point of frequent confusion deserves emphasis. Charaka’s first Medhya Rasayana is Mandukaparni, identified by most commentators and by the Ayurvedic Pharmacopoeia of India as Centella asiatica — not Brahmi (Bacopa monnieri). The two are listed as distinct herbs in the Pharmacopoeia, although the name “Brahmi” is applied to Bacopa across much of North India and in most modern commerce and research. Because nearly all modern clinical trials use Bacopa monnieri, I retain Bacopa in the evidence comparison below while keeping the classical identity clear. Classical tradition also regards Shankhapushpi as the foremost (shreshtha) of the medhya herbs. Ashwagandha (Withania somnifera) and Jatamansi (Nardostachys jatamansi) are not among Charaka’s named four, but are valued as rasayana and medhya herbs in the wider classical and nighantu literature and carry substantial modern evidence; I include them here for that reason rather than attributing them to a specific Medhya Rasayana verse.

Comparative Analysis: Category by Category

I group the comparison by cognitive function rather than by tradition, because that is how a real-world decision is actually made: you have a goal — consolidate memory, stay alert through a deadline, protect the aging brain — and you want the agent whose evidence best fits that goal. For each category I name the leading modern option, the closest Ayurvedic counterpart, and an honest assessment of which fits which situation.

Category 1: Memory Consolidation and Recall

Modern nootropic leader — Racetams (Piracetam, Aniracetam): The original nootropics, developed in the 1960s. Piracetam is thought to modulate AMPA-receptor function and membrane fluidity and to improve cholinergic transmission. The clinical reality is more modest than the reputation. The Cochrane systematic review of piracetam for dementia or cognitive impairment (Flicker & Grimley Evans) found an effect on clinician-rated global impression of change but no consistent benefit on specific measures of cognitive function, and concluded that the published evidence does not support routine clinical use. Evidence in healthy young adults is weaker still.

Ayurvedic equivalent — Brahmi (Bacopa monnieri): The most researched Medhya Rasayana in modern literature. A meta-analysis of nine randomized controlled trials (437 participants) of standardized Bacopa extract found a significant improvement in delayed word recall — the cognitive domain most consistently affected — together with signals on speed of attention (Trail-Making and choice reaction time). A defining feature is the time course: the pooled trials required at least 12 weeks of continuous use before effects emerged, unlike the racetams’ more acute action. The proposed mechanism — bacoside-mediated support of dendritic arborization, antioxidant activity in neural tissue, and modulation of cholinergic and BDNF pathways — is largely characterized in preclinical models, but is mechanistically distinct from the racetams, suggesting complementary rather than redundant actions.

Assessment: For sustained memory and learning support in healthy adults, Brahmi has a more convincing and better-replicated human evidence base than the racetams, with a long record of traditional use and a favourable safety profile. The trade-off is onset: weeks, not hours.

Category 2: Acute Wakefulness and Alertness

Modern nootropic leader — Modafinil: A prescription eugeroic that promotes wakefulness, primarily through dopamine-reuptake inhibition with downstream effects on histamine and orexin systems. It is well documented for sustaining alertness in shift work, jet lag, and sleep deprivation. In healthy, non-sleep-deprived subjects, a systematic review found that modafinil’s benefits are most consistent on attention, executive function, and learning, and become more apparent — not less — as task complexity increases. It carries dependency potential (lower than amphetamines), headache and anxiety risks, and is prescription-only in most countries.

Ayurvedic equivalent — Ashwagandha + Shankhapushpi combination: This pairing does not produce acute stimulant wakefulness; at equivalent single doses Ayurvedic herbs cannot match a pharmaceutical eugeroic for one-off alertness. Their strength is the opposite axis — sustained baseline function without a crash-and-anxiety cycle. Ashwagandha’s adaptogenic action lowers perceived stress and cortisol and supports sleep quality, which indirectly protects daytime cognition. In a randomized, placebo-controlled trial in adults with mild cognitive impairment, 600 mg/day of standardized root extract over eight weeks improved immediate and general memory, attention, and information-processing speed. Shankhapushpi contributes a calming, medhya effect traditionally used for anxious, scattered cognition.

Assessment: Modafinil wins for acute wakefulness in one-off situations (an overnight deadline, a critical shift). The adaptogenic combination wins for sustained baseline alertness and resilience over weeks without dependency or a withdrawal crash. These are different use cases, not direct competitors.

Category 3: Neuroprotection and Long-Term Brain Health

Modern approach — Lion’s Mane mushroom (Hericium erinaceus): A nutraceutical with growing evidence for nerve-growth-factor signalling via its hericenone and erinacine compounds. In a double-blind, placebo-controlled trial in older Japanese adults with mild cognitive impairment, Hericium erinaceus (3 g/day of dry powder, 16 weeks) improved scores on a standardized cognitive scale, with the benefit declining after the supplement was stopped. Most other supporting work for NGF/BDNF effects remains preclinical, and the human trials so far are small.

Ayurvedic equivalent — Brahmi + Ashwagandha + Jatamansi: The neuroprotective rationale for the Medhya Rasayanas is mechanistically broad, though much of it is preclinical. Bacopa shows antioxidant activity and support of dendritic growth and BDNF pathways in animal models; Withania somnifera’s withanolides (notably withanolide A) promote neurite outgrowth and dendrite formation in cultured neurons; Jatamansi’s sesquiterpenes show antioxidant and anxiolytic activity in animal studies. In humans, the strongest cognitive signals to date are Bacopa’s effect on delayed recall and Ashwagandha’s effect on memory and executive function in mild cognitive impairment, both cited above. I want to be explicit: the multi-target neuroprotective story is biologically plausible and promising, but long-term human outcome data — preventing decline over years — does not yet exist for any of these agents, Ayurvedic or nutraceutical.

Assessment: The Ayurvedic stack, particularly Brahmi + Ashwagandha, offers a mechanistically diverse and well-tolerated approach to brain aging with a reasonable short-term human evidence base. The case for long-term prevention is plausible but not yet proven by long-term trials.

Side-by-Side Comparison Table

The table below summarizes the agents discussed. “Best evidence use case” reflects where the human data are strongest, not a guarantee of benefit for any individual, and the effect-onset estimates assume standardized extracts at the research doses listed later in this article.

Compound	Category	Best Evidence Use Case	Effect Onset	Safety Profile
Modafinil	Pharmaceutical eugeroic	Acute sleep-deprivation alertness	1-2 hours	Prescription only; dependency risk; headache
Piracetam	Racetam nootropic	Cognitive impairment (evidence inconsistent)	Days to weeks	Generally well tolerated; limited long-term data
Lion’s Mane	Nutraceutical mushroom	Mild cognitive impairment; NGF support	8-16 weeks	Good; rare GI upset
Brahmi (Bacopa)	Medhya Rasayana	Delayed recall, learning, attention	~12 weeks	Good; mild GI in some
Ashwagandha	Medhya/Adaptogen	Memory in MCI, stress-impaired cognition	4-8 weeks	Good; thyroid stimulation caution
Shankhapushpi	Medhya Rasayana	Anxious cognition, sleep quality	2-4 weeks	Reasonable; minimal pregnancy data
Jatamansi	Medhya Rasayana	Anxiety, sleep, anxious cognition	1-2 weeks	Reasonable; avoid in pregnancy

Dosages Used in Clinical Research

One of the most common failures in herbal nootropic research is using sub-therapeutic doses. Here are the doses that produced significant results in the trials reviewed above, alongside the traditional preparations where they differ:

Brahmi (Bacopa monnieri): 300 mg standardized to roughly 55% bacosides daily; doses below ~200 mg tend to show minimal effect in RCTs
Ashwagandha: 300-600 mg standardized root extract daily; 600 mg was the dose associated with improved memory and cognition in the mild-cognitive-impairment trial
Shankhapushpi: classically given as kalka (fresh whole-plant paste); standardized extracts at 200-400 mg, or 1-2 g of churna, are the common commercial equivalents
Jatamansi: 500 mg standardized extract, or 1-2 g churna at bedtime
Guduchi: classically the fresh swarasa; 500 mg extract twice daily, or 3-5 g churna, in modern practice

The Stack for Different Users

Rather than “Ayurvedic vs modern nootropics,” the more productive question is: what combination serves your specific cognitive goal?

For students (exam preparation, learning new material): Brahmi 300 mg daily, with Shankhapushpi for anxious, scattered focus. Begin 10-12 weeks before the exam period to allow full onset, since the Bacopa evidence is built on roughly twelve weeks of continuous use. Add Jatamansi if exam anxiety or disturbed sleep is significant. For more on Brahmi dosage specifics based on clinical trial data, see our reference guide on Bacopa monnieri dosage from clinical trials.

For working professionals with cognitive fatigue: Ashwagandha 600 mg daily plus Brahmi 300 mg daily. The adaptogen-plus-medhya combination targets both the root (stress-mediated cognitive impairment) and the downstream symptom (impaired memory and focus).

For adults over 50 focused on long-term brain health: Brahmi 300 mg + Ashwagandha 600 mg, optionally with Lion’s Mane (Hericium erinaceus) where the nutraceutical evidence is judged worth combining. Set expectations honestly: the short-term cognitive data are reasonable, but no agent here is yet proven to prevent long-term decline.

For context on how these herbs work alongside conventional focus and concentration support, see also our guide to Ayurvedic herbs for concentration.

The Evidence Quality Question

A persistent and partly fair criticism of Ayurvedic cognitive herbs is evidence quality: many trials are small, short, single-centre, or concentrated in India, where publication bias is a genuine concern. That criticism has weakened over the past decade but has not vanished. Bacopa monnieri now has multiple randomized trials pooled in an independent meta-analysis showing a consistent effect on delayed recall, and Ashwagandha has a growing set of randomized, placebo-controlled trials on stress, sleep, and cognition from independent groups. What is still largely missing across the field is large, long-duration trials with hard outcomes, replicated outside the originating region. The honest summary is that the better Medhya Rasayana herbs have crossed from “traditional use only” into “supported by modest, repeatable human trials,” while the strongest neuroprotective claims remain mechanistically grounded but clinically unproven.

This article presents research comparisons for educational purposes and is not medical advice. Cognitive-enhancement supplements should be matched to individual health status. Modafinil and other pharmaceutical nootropics require a prescription and physician supervision. Herbal nootropics at the doses referenced have good safety profiles but should be discussed with a qualified healthcare provider or Ayurvedic practitioner, particularly if you take medications or have a health condition. Pregnant and breastfeeding women should avoid most nootropic supplements without medical guidance.

References: Charaka Samhita, Chikitsa Sthana 1 (Medhya Rasayana) | Kongkeaw et al., Bacopa monnieri meta-analysis, Journal of Ethnopharmacology 2014 | Choudhary et al., Ashwagandha and memory/cognition, Journal of Dietary Supplements 2017 | Mori et al., Hericium erinaceus and mild cognitive impairment, Phytotherapy Research 2009 | Battleday & Brem, Modafinil systematic review, European Neuropsychopharmacology 2015 | Flicker & Grimley Evans, Piracetam for dementia or cognitive impairment, Cochrane Database of Systematic Reviews.

References

Nothing in this article diagnoses or treats a medical condition. Use it as educational information and consult a qualified Ayurvedic practitioner or physician before starting herbs, supplements, detoxes, or therapeutic protocols, especially if pregnant, managing a condition, or taking medication.

Jatamansi: The Ayurvedic Valerian for Sleep, Anxiety, and Neuroprotection

Dr. Meera Iyer — Mon, 23 Feb 2026 01:41:17 +0000

Jatamansi in Ayurveda: Sleep, Mental Calm, Memory, and Responsible Use

Jatamansi (Nardostachys jatamansi) is an aromatic Himalayan medicinal plant whose dried rhizome is used in Ayurveda. The Ayurvedic Pharmacopoeia of India describes it as medhya, nidrajanana, varnya, and kushthaghna, and lists traditional applications that include anidra and manasaroga. These terms support its established Ayurvedic role in preparations intended for sleeplessness, mental disturbance, complexion, and certain skin conditions.

Modern laboratory and animal investigations have examined Jatamansi in relation to sleep, cognition, neuronal injury, seizures, and hair growth. Human investigation is much smaller and does not justify treating the herb as a replacement for psychiatric, neurological, or sleep medication. Its medical use also has an ecological dimension because the slow-growing Himalayan species is threatened by destructive rhizome collection and regulated in international trade.

Botanical Identity and Conservation Status

The accepted botanical name is Nardostachys jatamansi (D.Don) DC. Modern taxonomy places the species in the Caprifoliaceae family, within the valerian subfamily, while older pharmacopoeial and botanical references classify it under Valerianaceae. It is a perennial herb of Himalayan subalpine and alpine environments. The Ayurvedic Pharmacopoeia describes plants 10–60 cm high growing at approximately 3,000–5,000 metres.

The medicinal rhizome is dark brown, strongly aromatic, and covered by reddish-brown fibres formed from the remains of old leaf bases. This fibrous covering gives the underground portion its characteristic matted or hair-like appearance. The pharmacopoeial drug consists specifically of the dried rhizome, although roots and rhizomes are sometimes discussed together in experimental literature and commercial descriptions.

The species is assessed as Critically Endangered on the IUCN Red List. International trade is controlled through CITES Appendix II, where relevant documents may use the name Nardostachys grandiflora, a name treated as synonymous with Nardostachys jatamansi in current botanical databases. Appendix II does not prohibit all trade, but export and import must comply with the applicable permit and sustainability requirements.

Key Botanical and Ayurvedic Details

The following profile reflects the Jatamansi monograph in the Ayurvedic Pharmacopoeia of India rather than unreferenced commercial descriptions.

Accepted botanical name: Nardostachys jatamansi (D.Don) DC.
Modern family: Caprifoliaceae; older references use Valerianaceae
Pharmacopoeial part: Dried rhizome
Pharmacopoeial synonyms: Mamsi, Jata, and Jatila
Rasa: Tikta and Kashaya
Guna: Laghu
Virya: Shita
Vipaka: Katu
Dosha action: Tridoshanut, indicating alleviation of disturbed Vata, Pitta, and Kapha in the appropriate clinical context
Recorded karmas: Medhya, Varnya, Nidrajanana, and Kushthaghna
Recorded uses: Kushtha, Daha, Visarpa, Manasaroga, and Anidra

Ayurvedic Pharmacology

Jatamansi is bitter and astringent in taste, light in quality, cooling in potency, and pungent after digestion. The Ayurvedic Pharmacopoeia does not assign Madhura rasa to the drug. Its designation as tridoshanut also does not mean that the same dose or preparation is suitable for every person. Ayurvedic prescribing considers the dominant dosha pattern, digestive capacity, strength, age, season, associated symptoms, and accompanying medicines.

Ayurvedic term	Literal clinical sense	Traditional application
Medhya	Supportive of intellect and mental faculties	Used in appropriately selected preparations for memory, attention, and mental function
Nidrajanana	Promoting sleep	Relevant to Ayurvedic management of Anidra
Varnya	Supporting healthy complexion	Used in selected internal or external formulations concerned with skin appearance
Kushthaghna	Traditionally used in Kushtha	Applied within broader Ayurvedic treatment plans for classified skin disorders
Tridoshanut	Alleviating all three doshas	Interpreted according to the patient’s actual dosha disturbance rather than as universal suitability

Traditional Uses in Sleep and Mental Health

The pharmacopoeial indications Anidra and Manasaroga provide the clearest official basis for discussing Jatamansi in Ayurvedic sleep and mental-health practice. Anidra denotes disturbed or absent sleep within the Ayurvedic diagnostic framework. Manasaroga is a broad category of disorders involving the mind and should not be translated automatically into one modern diagnosis such as anxiety, major depression, psychosis, or dementia.

In practice, Jatamansi may be selected when sleep disturbance occurs with mental agitation, restlessness, heat-related discomfort, or other features compatible with its cooling and sleep-promoting profile. Some patients instead require treatment directed at pain, breathing disorders, endocrine disease, medication effects, depression, sleep apnoea, or another underlying cause. Persistent insomnia therefore warrants proper clinical assessment rather than indefinite self-treatment with a sedating herb.

The designation medhya distinguishes Jatamansi from a substance used merely to produce dullness. In Ayurvedic reasoning, a medicine may support sleep while also being incorporated into a broader plan for mental function. This traditional position is more precise than claims that the herb has been clinically proven to enhance intelligence or prevent neurodegenerative disease.

Phytochemical Profile

The Ayurvedic Pharmacopoeia identifies essential oil and resinous matter as principal constituents and specifies a minimum volatile-oil content for the crude drug. Modern chemical investigations have reported numerous sesquiterpenes together with coumarins, lignans, neolignans, and other constituents. The exact profile varies with plant material, geographical origin, storage, extraction method, and analytical technique.

Jatamansone, also called valeranone: A characteristic sesquiterpenoid frequently discussed in pharmacological literature on Jatamansi.
Nardosinone: A nardosinane-type sesquiterpene examined in neuronal cell models, particularly in experiments involving neurite development.
Nardostachone: One of several sesquiterpenoid constituents reported from the rhizome.
Nardal and jatamansic acid: Compounds isolated during phytochemical work that also evaluated hair-growth activity in an animal model.
Nardin: A constituent isolated from the rhizome in phytochemical investigations.
Lignans and neolignans: Additional classes documented in chemical studies of Jatamansi roots and rhizomes.

Individual constituents should not be assumed to reproduce the action of the whole pharmacopoeial drug. Conversely, the presence of a compound in a laboratory extract does not establish that ordinary powder, decoction, essential oil, and concentrated capsules have equivalent effects or safety.

Experimental Pharmacology

Most modern work on Jatamansi consists of cell-culture or animal experiments. These investigations help identify possible biological actions, but the extracts, doses, routes of administration, and disease models often differ substantially from ordinary Ayurvedic use in humans.

Sleep and Central Nervous System Activity

An animal study of Jatamansi rhizome powder reported reduced locomotor activity, shorter latency to pentobarbital-induced sleep, and prolonged sleeping time. At the evaluated dose, the preparation did not impair performance in the study’s rotarod and gross-behaviour assessments. These findings support investigation of a central depressant or sleep-facilitating action, but they do not establish a benzodiazepine-like GABA-A mechanism in humans.

Learning and Memory Models

An ethanolic extract was evaluated in mice using learning tasks and experimentally induced amnesia. The extract improved performance in the study and attenuated memory impairment produced by scopolamine, diazepam, and ageing. This is preclinical evidence involving a specific extract and animal doses; it does not establish prevention or treatment of dementia in people.

Experimental Neuroprotection

In a rat model involving 6-hydroxydopamine-induced dopaminergic injury, Jatamansi extract attenuated several behavioural, neurochemical, and oxidative changes associated with the lesion. The model is useful for studying mechanisms related to dopaminergic damage, but it is not equivalent to demonstrating clinical benefit in Parkinson’s disease.

Laboratory investigations have also examined Jatamansi constituents in relation to oxidative stress, inflammation, acetylcholinesterase activity, and experimentally produced neuronal injury. Such observations support continued pharmacological study while remaining distinct from evidence for treating Alzheimer’s disease, Parkinson’s disease, stroke, or other human neurological disorders.

Nardosinone and Neurite Development

Nardosinone has been tested in PC12D neuronal cell models. It enhanced neurite outgrowth induced by nerve growth factor and by certain experimental differentiating agents. In one investigation, nardosinone did not itself act as a direct neurotrophic factor; rather, it enhanced neurite development under stimulated conditions. Claims that it independently generates new nerves in humans go beyond these cell-culture findings.

Seizure Models

An ethanolic root extract increased seizure threshold in a maximal electroshock model in rats but was ineffective against pentylenetetrazole-induced seizures in the same published investigation. The extract also interacted with phenytoin in that model. Results therefore depend on the seizure model and preparation. A person with epilepsy must not add Jatamansi, stop medication, or change an anticonvulsant dose without supervision from the treating neurologist.

Hair-Growth Investigation

A phytochemical study evaluated Jatamansi rhizome extract, fractions, and isolated compounds in an animal hair-growth model. Activity was reported for the tested preparations, providing a basis for further investigation of traditional scalp use. The experiment does not establish a standard treatment for human alopecia, premature greying, autoimmune hair loss, or scarring disorders.

Human Evidence for Insomnia

The principal published human study commonly cited for sleep was a small open comparative trial of Tagara and Jatamansi in primary insomnia. Thirty-four participants were enrolled and thirty completed the trial, with fifteen completing treatment in each group. The Jatamansi group received 4 g of powder with milk three times daily after food for one month. Both groups improved on the study’s sleep assessments, while Tagara produced greater improvement on several reported outcomes.

This investigation was not a placebo-controlled trial of 500 mg twice daily, and it did not report the often-repeated comparison of a 38% PSQI improvement against 12% with placebo. The study dose was also much higher than the general 2–3 g powder dose listed in the Ayurvedic Pharmacopoeia. It should be understood as a small exploratory clinical study, not as a universal dosage protocol.

Claims that Jatamansi has clinically established antidepressant, anti-anxiety, anticonvulsant, cardioprotective, or dementia-preventing effects are not supported by comparable human trials. Its strongest verified position remains its traditional pharmacopoeial use, accompanied by preliminary human sleep data and a wider body of experimental pharmacology.

Evidence Overview

The following table separates pharmacopoeial tradition, human investigation, and experimental findings so that they are not treated as interchangeable forms of evidence.

Area	Type of support	Appropriate interpretation
Anidra and Nidrajanana	Ayurvedic Pharmacopoeia	Established traditional Ayurvedic indication and action
Primary insomnia	Small open comparative human study	Preliminary clinical support; not a definitive efficacy trial
Central depressant activity	Animal experiment	Supports caution regarding drowsiness and concurrent sedatives
Learning and memory	Mouse models	Experimental activity, not proof of human cognitive enhancement
Dopaminergic injury	6-OHDA rat model	Preclinical neuroprotective investigation
Neurite outgrowth	PC12D cell studies	Mechanistic cell-culture finding for nardosinone
Seizure threshold	Animal models with differing results	Not a substitute for anticonvulsant treatment
Hair growth	Animal-model phytochemical study	Supports further evaluation, not a confirmed alopecia therapy

Pharmacopoeial Preparations and Doses

The Ayurvedic Pharmacopoeia provides reference doses for authenticated crude Jatamansi. These figures are monograph standards, not individualized prescriptions. Concentrated extracts, capsules, essential oils, compound formulations, and products made from a different botanical species cannot be converted directly from the crude-drug dose.

Jatamansi Churna

For the powdered dried rhizome, the pharmacopoeial dose is 2–3 g. The timing, frequency, duration, and accompanying vehicle should be selected by a qualified Ayurvedic practitioner. The much larger regimen used in the small insomnia study should not be copied without clinical supervision.

Jatamansi Decoction

The pharmacopoeial quantity for preparing a decoction is 5–10 g of crude drug. A decoction is not equivalent milligram-for-milligram to dry powder or standardized extract because preparation changes the concentration and range of extracted constituents.

Jatamansyarka

The Ayurvedic Pharmacopoeia names Jatamansyarka as an important formulation containing Jatamansi. Its manufacture and use should follow an authoritative formulary or licensed product specification. A dose for one preparation should not be transferred to another product merely because both carry the name Jatamansi.

Compound Formulations

The composition of similarly named Ayurvedic compound medicines may differ by textual authority, regional tradition, manufacturer, and licensed formula. Consumers should check the complete label rather than assuming that Saraswatarishta, Manasamitra Vatakam, or another mental-health formulation always contains Jatamansi in the same amount. Complex formulations intended for psychiatric or neurological conditions require professional supervision.

Clinical Individualization

Jatamansi is not selected solely from a symptom such as “poor sleep.” Ayurvedic assessment may distinguish sleep disturbance associated with mental overactivity, heat, digestive discomfort, pain, respiratory obstruction, weakness, irregular routine, substance use, or an underlying illness. The same herb may be unsuitable when the cause, constitution, digestive capacity, or medication profile differs.

Sleep pattern: Difficulty falling asleep, repeated waking, early waking, nightmares, and daytime sleepiness require different assessment.
Digestive tolerance: Bitter and astringent medicines may be poorly tolerated by some patients or require a carefully selected vehicle.
Daytime alertness: Sedating effects are undesirable before driving, operating machinery, climbing, or safety-sensitive work.
Existing diagnoses: Sleep apnoea, bipolar disorder, severe depression, epilepsy, Parkinsonism, dementia, and cardiac symptoms require medical evaluation.
Concomitant treatment: Prescription medicines, other sedative herbs, alcohol, and cannabis products may alter tolerability or alertness.
Source of the herb: Conservation status and botanical authenticity should influence whether Jatamansi is selected at all.

Drug Interactions and Safety

Reliable human interaction and long-term toxicity data for Jatamansi are limited. The herb should not be described as free from dependence, cognitive effects, liver effects, or clinically important interactions merely because such outcomes have not been established in controlled trials. Product concentration and authenticity also vary.

Sedatives, Alcohol, and Driving

Because Jatamansi is classified as sleep promoting and has produced central depressant effects in animals, combining it with alcohol, benzodiazepines, barbiturates, opioid pain medicines, sedating antihistamines, antipsychotics, sleep medicines, or other calming herbs may increase drowsiness or impaired coordination. Avoid driving and hazardous work until individual effects are known. Any combination with prescription sedatives should be approved by the prescribing clinician.

Psychiatric and Neurological Medicines

Published data do not establish the specific serotonin-syndrome warning previously attributed to Jatamansi or a clinically proven monoamine-oxidase-inhibiting effect in patients. Even so, people taking antidepressants, antipsychotics, mood stabilizers, anticonvulsants, or Parkinson’s medicines should use it only after medication review. The animal interaction observed with phenytoin is an additional reason not to self-combine Jatamansi with antiseizure therapy.

Pregnancy, Breastfeeding, and Children

Safety during pregnancy and breastfeeding has not been established, so medicinal use is generally avoided unless specifically directed by a qualified healthcare professional. Paediatric use also requires individualized advice. Adult pharmacopoeial doses must never be scaled casually for an infant or child.

Adverse Effects and Medical Review

Possible intolerance may include excessive sleepiness or digestive discomfort, although the frequency of adverse effects has not been defined in large human studies. Stop the product and obtain medical advice for marked confusion, fainting, breathing difficulty, rash, persistent vomiting, worsening mood symptoms, unusual agitation, or seizure activity. Persistent insomnia, palpitations, severe anxiety, or neurological symptoms also require diagnosis rather than repeated self-dosing.

Product Quality

Use a licensed product that identifies the full botanical name, plant part, batch, manufacturer, and recommended dose. Jatamansi may be confused or substituted in commerce with Tagara, now commonly identified as Valeriana jatamansi and historically called Valeriana wallichii. Although both are aromatic Himalayan medicinal plants, they are not interchangeable species. Pharmacopoeial examination, microscopy, and chromatographic identity testing help distinguish authentic material.

As with other Ayurvedic products, poor manufacturing can introduce microbial contamination, pesticides, undeclared pharmaceuticals, or excessive metals. Choosing a reputable manufacturer with appropriate testing is especially important for products intended for prolonged internal use.

Sustainability and Ethical Sourcing

Harvesting the medicinal rhizome usually destroys the plant. Slow regeneration, habitat pressure, and commercial collection have therefore contributed to serious population decline. Conservation is part of clinically responsible use, not merely an optional purchasing preference.

Prefer documented cultivated material: Cultivation reduces direct pressure on wild populations when the supply chain is genuine and traceable.
Check legal trade: International shipments should comply with CITES documentation and the laws of the exporting and importing countries.
Avoid anonymous loose material: Unlabelled rhizomes provide little assurance of species identity, collection method, contamination control, or legal origin.
Use only when specifically indicated: Routine inclusion in every sleep or relaxation blend increases demand without respecting the herb’s conservation status.
Consider appropriate alternatives: A practitioner may select another medicine when Jatamansi’s particular Ayurvedic profile is unnecessary.

India’s medicinal-plant programmes include support for conservation, cultivation, and quality planting material for high-priority species such as Jatamansi. Cultivation must still be accompanied by correct botanical identification and suitable high-altitude agricultural practices.

External and Aromatic Use

The strongly aromatic rhizome yields an essential oil used in perfumery and in some external preparations. Jatamansi may also be incorporated into scalp oils, massage oils, or other traditional topical products. External tradition and animal hair-growth experiments do not establish that the essential oil treats human insomnia, alopecia, eczema, psoriasis, or neurological disease.

Head and Scalp Oils

Standardized Jatamansi-containing oils have been described for head-massage applications, and the pharmacopoeial actions Varnya and Kushthaghna provide an Ayurvedic basis for selected skin and cosmetic uses. The oil should be assessed as a complete formulation because the base oil, concentration, processing method, and accompanying herbs affect its properties.

Essential-Oil Precautions

Essential oil is far more concentrated than rhizome powder and should not be swallowed. For skin application it should be suitably diluted in a carrier oil, tested first on a small area, and kept away from the eyes and mucous membranes. Discontinue use if burning, swelling, or dermatitis develops. Diffusion may provide aroma, but a claim of clinically meaningful sedation through inhalation has not been established.

Jatamansi in Ayurvedic Mental-Health Practice

Jatamansi’s verified Ayurvedic descriptors are Medhya and Nidrajanana, with Manasaroga and Anidra among its listed uses. These terms support a traditional role in carefully selected mental-health and sleep formulations. They do not make Jatamansi itself a form of Sattvavajaya; Sattvavajaya is an Ayurvedic psychotherapeutic approach involving regulation of the mind rather than the name of an herbal category.

Herbal treatment is only one part of Ayurvedic care for disturbed sleep or mental distress. Daily routine, diet, sensory regulation, counselling, physical activity, breathing practices, and treatment of contributing disease may all be relevant. Constitutional and dosha assessment can help determine whether Jatamansi fits the patient’s pattern, but it should not delay psychiatric or neurological care when urgent symptoms are present.

Practical Summary

Jatamansi is an authentic Ayurvedic drug with clearly recorded pharmacopoeial properties and uses. Its bitter and astringent taste, light quality, cooling potency, pungent post-digestive effect, Medhya and Nidrajanana actions, and traditional indications for Anidra and Manasaroga are well documented. Experimental investigations provide plausible leads for sleep, cognition, neuronal protection, seizure modulation, and hair growth, while human evidence remains centred on a small open insomnia study.

Responsible use requires three safeguards: accurate botanical identification, medical review of sedating or neurological medicines, and conservation-conscious sourcing. Jatamansi should not replace prescribed treatment for insomnia, anxiety disorders, depression, epilepsy, Parkinson’s disease, dementia, arrhythmia, or any other serious condition.

This article is for educational purposes. Consult a qualified Ayurvedic practitioner and an appropriate healthcare provider before using Jatamansi, particularly during pregnancy or breastfeeding, for a child, or alongside prescription medicines.

References

Brahmi vs Shankhpushpi: Which Nootropic Herb Is Right for You?

Dr. Meera Iyer — Sat, 21 Feb 2026 16:47:30 +0000

Two Herbs, One Question: Which Ayurvedic Cognitive Herb Fits the Need?

“Brain tonic” is too broad for a precise Ayurvedic choice. Poor retention, stress-related distractibility, disturbed sleep, mental fatigue, and progressive cognitive change are not interchangeable complaints. Brahmi and Shankhapushpi are both described as medhya in authoritative Ayurvedic sources, but their botanical identities, classical attributes, doses, and levels of modern clinical study differ substantially.

A second distinction is essential. The well-known passage in Charaka Samhita, Chikitsa Sthana 1/3/30–31, names Mandukaparni juice, Yashtimadhu powder with milk, Guduchi juice, and Shankhapushpi paste as especially intellect-promoting rasayanas. Bacopa monnieri is not one of the four drugs named in that passage. Nevertheless, the Ayurvedic Pharmacopoeia of India separately identifies Bacopa monnieri as Brahmi and assigns it the actions medhya and rasayana. Both herbs therefore have authentic Ayurvedic standing, but not through the same textual statement.

Brahmi (Bacopa monnieri): The Better-Studied Option for Memory

The Ayurvedic Pharmacopoeia of India defines Brahmi as the dried whole plant of Bacopa monnieri (Linn.) Wettst. Modern products may contain whole-plant powder or extracts standardized to selected saponins; these forms are not dose-equivalent and should not be treated as interchangeable.

Classical Ayurvedic Profile

Its recorded pharmacopoeial attributes are:

Rasa: madhura, tikta, kashaya — sweet, bitter, and astringent
Guna: laghu and sara — light and mobile or flowing
Virya: shita — cooling
Vipaka: madhura — sweet post-digestive effect
Karma: includes medhya, rasayana, matiprada, Vatahara, and Kaphahara

The pharmacopoeia lists Sarasvatarishta, Brahmi Ghrita, Brahmi Vati, Sarasvata Churna, and Smritisagara Rasa among important formulations associated with Brahmi. Raw herb, extract capsules, and compound formulations remain therapeutically distinct.

Human Clinical Evidence

Bacopa has a larger human evidence base than Convolvulus pluricaulis. A 2001 randomized, double-blind, placebo-controlled trial of a standardized extract reported improvements after 12 weeks in visual information-processing speed, learning rate, memory consolidation, and state anxiety. A separate 2002 trial in adults aged 40–65 found a significant effect on retention of newly learned word pairs, with the pattern suggesting reduced forgetting rather than a broad improvement across every memory measure.

A 2012 systematic review found the most consistent signal in memory free recall, while effects in other cognitive domains were less consistent. A 2014 meta-analysis of randomized controlled trials concluded that Bacopa had potential cognitive benefits, particularly for speed of attention, while also calling for larger and better-designed trials. Standardized Bacopa extracts may improve selected outcomes in some adults after repeated use, but they are not established dementia treatments or universal remedies for poor concentration.

More recent evidence also argues against certainty. A 12-week randomized trial published in 2025 found no greater improvement in cognitive performance than placebo, although it reported signals for reduced stress and fatigue. Differences among extracts and study designs make product-specific interpretation important.

What Is Known About Mechanism

Bacopa contains dammarane-type triterpenoid saponins commonly grouped under the term bacosides. Laboratory and animal studies have examined antioxidant activity, cholinergic signaling, monoamine systems, synaptic plasticity, and neuroprotective pathways. Some human studies have also measured acetylcholinesterase-related outcomes. These findings do not justify equating Bacopa with donepezil or reducing its effects to one neurotransmitter pathway.

Shankhapushpi (Convolvulus pluricaulis): Classical Medhya Rasayana with Limited Human Data

The Ayurvedic Pharmacopoeia of India defines Shankhapushpi as the whole plant of Convolvulus pluricaulis Choisy. It also notes that Clitoria ternatea and Evolvulus alsinoides are used as Shankhapushpi in some parts of India. A label carrying the common name “Shankhpushpi” may therefore contain a different species from the one used in a study or monograph.

Classical Ayurvedic Profile

For pharmacopoeial Convolvulus pluricaulis, the recorded Ayurvedic attributes are:

Rasa: tikta, kashaya — bitter and astringent
Guna: sara — mobile or flowing
Virya: shita — cooling
Vipaka: madhura — sweet post-digestive effect
Karma: includes medhya, rasayana, balya, ayushya, Kaphahara, Pittahara, and mohanashaka

Charaka’s medhya-rasayana passage specifies Shankhapushpi in paste form. The pharmacopoeia lists Brahmi Ghrita, Agastyaharitaki Rasayana, Brahma Rasayana, Manasamitra Vataka, Gorocanadi Vati, and Brahmi Vati among important formulations associated with Shankhapushpi. A formulation name containing “Brahmi” does not establish that every modern product contains both herbs.

Experimental Evidence and Its Limits

Animal studies have reported memory-related, anxiolytic, and central nervous system depressant effects from Convolvulus pluricaulis extracts. A 2011 study evaluated several extracts in rodents and found activity in learning, memory, anxiety, and locomotor models, with results varying by extract and dose. Phytochemical investigations describe alkaloids, coumarins, flavonoids, and sterols, with profiles varying by material and extraction method.

Human clinical evidence for authenticated Convolvulus pluricaulis remains sparse. It is therefore inaccurate to assign it a proven four-to-six-week onset, a validated GABA mechanism in patients, or superiority over Bacopa for anxiety. Its contemporary use is best framed as a classical Ayurvedic choice requiring individualized prescribing, not a standardized nootropic protocol.

Head-to-Head Comparison

No robust direct human trial establishes that one of these herbs is categorically superior to the other. A useful comparison separates classical pharmacopoeial information from modern clinical evidence.

Parameter	Brahmi (Bacopa monnieri)	Shankhapushpi (Convolvulus pluricaulis)
Official drug part	Dried whole plant	Whole plant
Classical standing	Medhya and rasayana in the API monograph	One of Charaka’s four specified medhya rasayanas; also medhya and rasayana in the API
Rasa	Madhura, tikta, kashaya	Tikta, kashaya
Guna	Laghu, sara	Sara
Virya	Shita	Shita
Vipaka	Madhura	Madhura
Dosha-related API karma	Vatahara and Kaphahara are listed	Kaphahara and Pittahara are listed
API powder dose	1–3 g	3–8 g
Modern evidence	Several small human trials and systematic reviews; outcomes are mixed	Mainly animal and laboratory studies; limited authenticated human data
Common practical issue	Extract strengths and bacoside specifications differ	Several botanical species may be sold under the same common name

Clinical Decision Framework

Ayurvedic selection should consider the person, the complaint, digestive tolerance, concurrent medicines, and the exact preparation. Constitution alone is insufficient, and neither herb should be chosen solely from an online dosha quiz.

When Brahmi May Be the More Defensible Starting Point

Brahmi is the more evidence-supported option when the goal is a time-limited trial for memory retention or selected attention outcomes in an otherwise medically assessed adult. Considerations include:

Difficulty retaining newly learned information without sudden or progressive neurological symptoms
A preference for a product standardized in the same way as a published human trial
Willingness to use it consistently for the trial period rather than expecting an immediate stimulant effect
Access to professional review of gastrointestinal tolerance, thyroid status, and possible medicine interactions

When Shankhapushpi May Be Considered

Shankhapushpi may be selected within an Ayurvedic plan when its classical medhya, rasayana, Pittahara, and Kaphahara profile fits the assessed presentation. Practical requirements are:

Confirmation that the product contains Convolvulus pluricaulis rather than an unspecified substitute
Use of the whole herb or a clearly characterized preparation rather than assuming all syrups are equivalent
Practitioner supervision when the complaint includes anxiety, insomnia, seizures, thyroid disease, or regular medication use
Realistic expectations, because a clinically validated onset time and comparative superiority have not been established

Should They Be Combined?

A combination is not automatically more effective. Classical and proprietary formulations may contain multiple medhya herbs, but their rationale, proportions, processing, and adjuvants are formulation-specific. A fixed schedule of 300 mg Bacopa extract plus 3 g Shankhapushpi is neither a universal classical protocol nor a validated combined regimen. Combination use should follow a qualified practitioner’s assessment.

Dosing and Dosage Forms

Dose must be tied to the exact material. A gram dose of whole-plant powder cannot be converted directly into a milligram dose of concentrated extract, and commercial syrups may also contain several ingredients.

Brahmi

The Ayurvedic Pharmacopoeia of India gives 1–3 g of the drug in powder form. Several adult cognition trials used about 300 mg daily of a particular standardized extract, but the extract specification is part of the dose and cannot be omitted. Brahmi Ghrita is an official classical formulation associated with the herb; its dose should follow the applicable formulary, product directions, and practitioner advice rather than being inferred from raw-herb dosing.

Shankhapushpi

The pharmacopoeial dose is 3–8 g of the drug in powder form. It does not establish a universal dose for juice, syrup, tablets, or concentrated extracts. Because several species circulate under the common name, check the botanical name and plant part.

Ghee, Milk, and Black Pepper

Ghee has an established place in Ayurvedic dietetics and in classical medicated-ghee formulations used for medhya purposes. That use does not prove that ghee increases absorption of every constituent in either herb. Likewise, adding black pepper is not automatically appropriate; piperine can alter drug metabolism, and no universal Brahmi–Shankhapushpi protocol requires it.

Safety Considerations and Interactions

“Natural” does not mean interaction-free. Product authentication, dose, duration, age, pregnancy status, medical conditions, and concurrent medicines all affect safety.

Brahmi: Human trials most often report gastrointestinal effects such as increased stool frequency, abdominal cramps, and nausea. Caution is appropriate with thyroid disease or thyroid hormone, cholinergic or anticholinergic medicines, and drugs affected by CYP enzymes.
Shankhapushpi: Human safety and interaction data for authenticated Convolvulus pluricaulis are limited. Do not use animal thyroid findings to alter levothyroxine, antithyroid medicine, or endocrine care.
Pregnancy and breastfeeding: Avoid self-prescribing either herb because adequate human safety data and product consistency are lacking.
Children and older adults: Dosing should be individualized by a qualified Ayurvedic practitioner or healthcare professional, especially when other medicines are used.
Persistent symptoms: New, worsening, or progressive memory change, confusion, severe anxiety, sleep disruption, or functional decline requires medical evaluation rather than treatment with a nootropic supplement alone.

Consult a qualified Ayurvedic practitioner and the relevant healthcare provider before starting either herb, particularly if you are pregnant, breastfeeding, treating a thyroid or neurological condition, or taking prescription medication.

Bottom Line

Brahmi and Shankhapushpi are not interchangeable “brain herbs.” Bacopa monnieri has the stronger human research base for selected memory and attention outcomes, although results are mixed and extract-specific. Convolvulus pluricaulis has a particularly clear classical position as one of Charaka’s medhya rasayanas, but its modern human evidence is much thinner and botanical substitution is a major practical concern. The sound choice depends on authenticated material, the precise clinical goal, the Ayurvedic assessment, and safety review—not on claims of a universal best nootropic.

References

Medhya Rasayana Stack for Professionals: Brain Protocol for Burnout

Vikram Desai — Sun, 25 Jan 2026 11:30:22 +0000

Burnout Is Not a Mindset Problem

A Medhya Rasayana approach to professional burnout begins with a simple correction: burnout is not laziness, weakness, or a lack of ambition. The World Health Organization describes burnout as an occupational phenomenon arising from chronic workplace stress that has not been successfully managed, with exhaustion, mental distance or cynicism, and reduced professional efficacy as its core features. Ayurveda approaches this pattern through restoration rather than force: stabilize sleep, calm aggravated vata, rebuild ojas and bala, support agni, and then use medhya herbs to nourish memory, attention, learning, and steadiness of mind.

In Ayurvedic language, the person who is mentally “running hot and empty” often shows a combined picture of prana vata disturbance, disturbed nidra, variable agni, depleted ojas, and reduced steadiness of smriti, dharana, and medha. Medhya Rasayana is therefore not a productivity hack. It is a restorative framework that belongs with food, sleep, routine, breath regulation, and carefully chosen herbs.

Diagnosing Cognitive Burnout: Are You There?

The table below is a practical self-assessment guide, not a medical diagnosis. It helps decide whether the emphasis should be lifestyle repair, a mild medhya support plan, or supervised care with medical evaluation.

Stage	Typical Pattern	Ayurvedic Reading	Protocol Intensity
Early strain	Afternoon tiredness, mild focus lapses, delayed sleep, irritability after overwork	Vata aggravation, prana vata strain, early ojas stress	Routine, sleep repair, warm meals, one or two gentle medhya supports
Active burnout	Mental fog, poor recall, low motivation, emotional dullness, restless or unrefreshing sleep	Ojas and bala depletion, disturbed nidra, prana vata and sadhaka pitta overload	Structured 90-day Medhya Rasayana plan with diet and practitioner guidance
Severe or chronic burnout	Inability to sustain work, marked exhaustion, depressive symptoms, anxiety, persistent insomnia, physical fatigue	Deep ojas depletion, majja-dhatu strain, possible overlapping medical or mental health condition	Qualified Ayurvedic and medical supervision; rule out thyroid, iron, B12, sleep, mood, and other causes

Charaka’s Four Medhya Rasayanas

Charaka Samhita describes four principal Medhya Rasayana preparations in Rasayana Adhyaya: Mandukaparni svarasa, Yashtimadhu churna with milk, Guduchi juice, and Shankhapushpi paste. This is the classical core. Brahmi, Ashwagandha, and Jyotishmati are valuable herbs, but they should not be mislabeled as the exact four-herb Charaka list.

Mandukaparni / Centella asiatica: Mandukaparni is one of Charaka’s Medhya Rasayanas and is listed in the Ayurvedic Pharmacopoeia of India as Medhya, Rasayana, Ayushya, Smritiprada, Balya, Dipana, and Hridya. It suits burnout patterns where mental dullness, reduced recall, and heat-aggravated fatigue are present. API lists the dried whole plant dose as 3-6 g in powder form for adult oral guidance.

Yashtimadhu / Glycyrrhiza glabra: Charaka includes Yashtimadhu powder taken with milk in the Medhya Rasayana group. API describes Yashtimadhu as madhura in rasa, guru and snigdha in guna, shita in virya, madhura in vipaka, and balya. Its nourishing nature makes it relevant when burnout has dryness, depletion, voice strain, and pitta-vata irritation. Because licorice can be unsuitable in hypertension, kidney or heart disease, low potassium tendency, pregnancy, or certain medicines, it should be used only with appropriate guidance.

Guduchi / Tinospora cordifolia: Guduchi is included by Charaka as a Medhya Rasayana and is listed in API as Rasayana, Balya, Dipana, Tridoshashamaka, and Raktashodhaka. It is especially useful in a restorative protocol when burnout is accompanied by poor appetite, heaviness after meals, low resilience, or a sense of depleted immunity. API lists 3-6 g powder or 20-30 g for decoction guidance in adults.

Shankhapushpi / Convolvulus pluricaulis: Shankhapushpi is described by Charaka as especially intellect-supporting, and API lists it as Medhya, Rasayana, Balya, Ayushya, Pittahara, Kaphahara, and Mohanashaka. It belongs in burnout protocols where mental restlessness, overthinking, poor sleep rhythm, and lack of calm concentration are dominant. API lists 3-8 g powder for adult oral guidance. Since different plants are used regionally under the name Shankhapushpi, botanical authentication matters.

Supportive Herbs for a Burnout-Focused Brain Stack

A practical burnout stack can include herbs beyond Charaka’s four, provided their role is stated accurately. The goal is not to take every herb at once, but to match the person’s current pattern: restoration first, medhya support second, sharper stimulation last or not at all.

Brahmi / Bacopa monnieri: Brahmi is listed in the Ayurvedic Pharmacopoeia of India as Medhya, Rasayana, Ayushya, Matiprada, Vatahara, and Kaphahara. It is a steady medhya herb for learning, memory, attention, and mental endurance. It is not best understood as a quick stimulant; its role is gradual support. API lists 1-3 g powder for adult oral guidance. Standardized extracts should follow practitioner or product-specific dosing.

Ashwagandha / Withania somnifera: Ashwagandha is not one of Charaka’s four Medhya Rasayanas, but it is a major Rasayana and Balya herb in API, with Vata-Kapha pacifying action. In burnout, it is most relevant when the person is exhausted, under-slept, physically depleted, tense, and unable to recover after work. API lists 3-6 g root powder for adult oral guidance. Modern extracts vary, so use labeled dosing and professional guidance rather than combining high doses casually.

Jyotishmati / Celastrus paniculatus: Jyotishmati is listed in API with Medhya action by prabhava, but it is also ushna and tikshna, with actions that include virechaka and vamaka. That makes it a potent herb, not a casual daily focus supplement. It may be considered only when a qualified practitioner decides it is appropriate for the person’s constitution, digestive strength, heat level, and medical history. API lists 1-2 g seed or 5-15 drops oil for adult oral guidance.

The 90-Day Medhya Rasayana Protocol

This protocol is a structured template to discuss with a qualified Ayurvedic practitioner. It begins with restoration because medhya herbs work best when sleep, digestion, and daily rhythm are no longer being damaged every day.

Days 1-14: Foundation Phase

Fix the sleep anchor first: a consistent bedtime, dim light in the late evening, and a device-off period before sleep.
Reduce stimulants after the morning. Avoid using caffeine to push through exhaustion.
Use warm, freshly cooked meals with adequate healthy fat. A small amount of ghee with lunch or dinner may suit people who digest it well.
Choose Ashwagandha only when it fits the person: dry fatigue, vata-type exhaustion, poor recovery, and no contraindication. Otherwise begin with food, routine, and breath practice alone.

Days 15-30: Add One Medhya Base

Choose Brahmi when the main complaint is learning fatigue, poor recall, and scattered attention.
Choose Mandukaparni when the pattern includes mental fatigue with heat, irritability, and reduced memory steadiness.
Do not add multiple new herbs on the same day. Introduce one support at a time so tolerance and response are clear.

Days 31-60: Deepen the Rasayana Direction

Add Shankhapushpi when overthinking, restlessness, disturbed sleep rhythm, and lack of calm concentration remain prominent.
Consider Guduchi when the burnout picture includes weak digestion, low resilience, heaviness, and recurrent inflammatory or pitta-kapha features.
Consider Yashtimadhu with milk only when it is appropriate for the person’s blood pressure, potassium status, kidney and heart health, and medication profile.

Days 61-90: Consolidate, Do Not Overload

Keep one main medhya herb and one restorative support rather than building a heavy stack by default.
Use Jyotishmati only under direct practitioner supervision because of its ushna, tikshna, virechaka, and vamaka profile.
Review sleep, digestion, energy, mood, recall, and work capacity before deciding whether to continue, pause, or simplify the protocol.

Expected Milestones and Adjustment Points

A Rasayana plan is assessed by steadiness, recovery, digestion, sleep, and mental clarity, not by a sudden burst of forced productivity. The following checkpoints help keep the protocol grounded.

Days 3-14: Sleep timing, evening restlessness, digestion, and morning heaviness should begin to move in the right direction.
Days 15-30: Focus dips may become less dramatic, and morning clarity may feel more reliable.
Days 31-60: Emotional reactivity, overthinking, and recall difficulty should be reassessed. If symptoms are worsening, simplify the protocol and seek professional evaluation.
Days 61-90: Reassess baseline work capacity, sleep quality, mood, digestion, memory, and resilience. Maintenance should be lighter than the recovery phase.

If there is no meaningful improvement by the middle of the protocol, or if exhaustion, low mood, anxiety, insomnia, or cognitive difficulty is severe, medical evaluation is necessary. Thyroid dysfunction, iron deficiency, vitamin B12 deficiency, sleep apnea, depression, anxiety disorders, medication effects, and chronic infection or inflammation can mimic or worsen burnout.

The pranayama stress breathing practice can be paired with this approach because breath regulation, routine, food, and herbs support different parts of the recovery process. For readers comparing adaptogenic support, the Ashwagandha vs Rhodiola comparison can be used as a companion article while keeping the present protocol rooted in Medhya Rasayana.

Medical disclaimer: This content is for educational purposes only. Cognitive burnout can overlap with depression, anxiety disorders, thyroid disease, anemia, vitamin B12 deficiency, sleep disorders, and other medical conditions. Herbal supplements can interact with medicines and may be unsuitable during pregnancy, breastfeeding, liver disease, kidney disease, heart disease, hypertension, autoimmune disease, thyroid disorders, or psychiatric medication use. Consult a qualified Ayurvedic practitioner and healthcare provider before beginning any supplement protocol.